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ABSTRACT
Objective: Bronchial thermoplasty (BT) is a novel treatment for severe asthma. Its mode of action and
ideal target patient group remainpoorly defined, thoughclinical trials provided someevidenceoneffi-
cacy and safety. This study presents procedural and short-term safety evidence from routine UK clin-
ical practice.Methods: Patient characteristics and safety outcomes (procedural complications, 30-day
readmission and accident and emergency (A&E) attendance, length of stay) were assessed using two
independent data sources, the British Thoracic Society UK Difficult Asthma Registry (DAR) and Hospi-
tal Episodes Statistics (HES) database. A matched cohort (with records in both) was used to estimate
safety outcome event rates and compare themwith clinical trials. Results: Between June 2011 and Jan-
uary 2015, 215 procedure records (83 patients; 68 treated in England) were available from DAR and 203
(85 patients) from HES. 152 procedures matched (59 patients; 6 centres), and of these, 11.2% reported
a procedural complication, 11.8% resulted in emergency respiratory readmission, 0.7% in respiratory
A&E attendance within 30 days (20.4% had at least one event) and 46.1% involved a post-procedure
stay. Compared with published clinical trials which found lower hospitalisation rates, BT patients in
routine clinical practice were, on average, older, had worse baseline lung function and asthma quality
of life. Conclusions: A higher proportion of patients experienced adverse events compared with clini-
cal trials. The greater severity of disease amongst patients treated in clinical practice may explain the
observed rate of post-procedural stay and readmission. Studyof long-term safety and efficacy requires
continuing data collection.
Introduction
Bronchial thermoplasty (BT) is a novel treatment for
severe asthma. Thermal energy is applied to the airway
wall to reduce excessive bronchial smooth muscle, lim-
iting its ability to contract and narrow the airway. It is
normally delivered in three bronchoscopic procedures,
approximately 3–4 weeks apart.
Clinical trials [1–3] have provided some evidence to
support the efficacy and short-term safety of BT and 5-
year safety data has also been published [4–6]. However
two of the trials were performed in patients with mod-
erate to severe asthma and only one of these trials had a
sham control arm. More evidence is required to confirm
the long-term benefits of BT [7,8] and several studies call
for further investigation to understand themode of action
CONTACT Julie Burn julie.burn@nuth.nhs.uk Northern Medical Physics and Clinical Engineering, The Newcastle upon Tyne Hospitals NHS Foundation
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and to define the subtypes who would benefit the most
[9–11]. There has been little information published to
date about the safety of BT in routine clinical practice in
people withmore severe asthma than those who took part
in the trials. A case series of 8 patients [12] and another of
4 patients [13] demonstrated safety of BT in more severe
asthmatics. In addition, a study of 10 patients in a cen-
tre which previously took part in the trials did not find
any safety concerns at 12 months post-procedure [14].
Adverse events reported to be related to BT have included
lung abscess [15], recurrent lung atelectasis [16] and lobar
consolidation and ground glass opacities [17].
Although BT may have potential as a promising
treatment for severe asthmatics, a Cochrane Review in
2014 [18] concluded that the overall quality of evidence
©  Julie Burn, Andrew J. Sims, Kim Keltie, Hannah Patrick, Sally A. Welham, Liam G. Heaney, and Robert Niven. Published with license by Taylor & Francis Group, LLC.
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for the procedure is ‘moderate’ and recommended the
systematic collection of data in an independent clinical
registry. International guidelines on the treatment of
severe asthma [19] stated that BT should only be per-
formed in the context of an Institutional Review Board
approved independent systematic registry or a clinical
study, due to the low confidence in reported evidence.
Prior to these recommendations, in 2012 in the UK, the
National Institute for Health and Care Excellence (NICE)
reviewed BT [20] concluding that published evidence
showed some short-term improvement in symptoms and
quality of life, reduced exacerbations and admissions to
hospital, but more evidence was required on long-term
safety. NICE recommended the collection of safety and
efficacy outcomes through the British Thoracic Society
(BTS) UK Difficult Asthma Registry [21] (DAR) and
their guidance instructs clinicians to submit details of all
patients undergoing the BT procedure. DAR was estab-
lished in 2006 to collect data about patients with difficult
asthma and was subsequently expanded to collect data
for BT. The safety and efficacy outcomes and the specific
fields to be added to the registry pages were agreed
through consultation with clinicians in the BTS Severe
Asthma Network and supported by NICE (see online
supplementary material). Guidance was issued to all cen-
tres undertaking BT regarding pre-treatment, follow-up
and data collection in DAR to improve standardisation
of patient care and achieve consistent data capture.
Routinely collected hospital administrative data may
also provide a means of evaluating outcomes of pro-
cedures in routine clinical practice. Hospital Episode
Statistics [22] (HES) is a data warehouse containing
details of all admissions, outpatient appointments and
accident and emergency (A&E) attendances at National
Health Service (NHS) hospitals in England. Each episode
of care contains coded procedure and diagnosis informa-
tion allowing for identification of procedures of interest
and occurrence of complications.
This study supports the recommendations of NICE
Guidance [20], and also aligns with current interna-
tional efforts to improve data collection outside of a
clinical trial setting for new technologies [23, 24]. The
aim of this paper is to present procedural and short-
term safety evidence for BT using data collected dur-
ing routine clinical practice in the UK. We used two
independent data sources (DAR and HES) to assess
selected safety outcomes including procedural com-
plications, readmissions, A&E attendances and post-
procedure stay. We also compared patient characteris-
tics and safety outcomes with published trials. Prelim-
inary results of this study were presented previously
[25].
Methods
Data extraction
BT baseline, procedure and follow-up records in DAR
on 31 January 2015 for patients having BT between
June 2011 and January 2015 were extracted for analy-
sis. In accordance with registry information governance
requirements, the data were provided in anonymised
form. Patients had previously given fully informed writ-
ten consent for their information to be entered into DAR.
Ethics approval for the registry was provided by the
Office for Research Ethics Committees Northern Ireland
(10/NIR02/37).
Records representing episodes of care in the period
1st April 2011 to 31st January 2015, which involved a BT
procedure, were identified from HES. From these pro-
cedure episodes, a list of unique pseudonymised person
identifiers was extracted and used in a second search of
HES to extract all episodes of care, including readmis-
sions and A&E attendances following BT procedures, to
create a longitudinal record for each BT patient. A full
description of the search and filtering criteria is included
in the online supplementary material.
HES data are only applicable to England, but DAR also
accepts data from Scotland, Wales and Northern Ireland.
Total UK coverage of BT procedures in DARwas assessed
by contacting the sole manufacturer of the BT device to
confirm whether there had been any BT procedures car-
ried out in UK centres which were not contributing data
to DAR.
Patient characteristics
Age at first procedure and gender were retrieved from
both sources; baseline asthma status, including pre-
bronchodilator forced expiratory volume in 1 second
(FEV1) (%of predicted) andAsthmaQuality of LifeQues-
tionnaire (AQLQ) score (a higher AQLQ score represents
better quality of life) [26], was obtained from DAR only.
Comparisonwith data from previous clinical trials
Patient demographic data, lung function and asthma
related quality of life (AQLQ) were compared with pub-
lished clinical trials [1–3]. Safety outcomes including
rates of procedural complications, readmissions and A&E
attendances within 30 days were compared with reported
hospitalisation rates for the three published clinical trials.
Identification of safety outcomes
BT procedures in DAR were reviewed for any events
related to safety mentioned in any of the data fields, i.e.
including, but not restricted to the free text ‘Unanticipated
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Procedural Morbidity’ field. The severity of the reported
respiratory events, including mild reactions, unantici-
pated events and device problems, was reviewed at regular
BT steering groupmeetings at whichNICE, aNICEExter-
nal Assessment Centre, the BTS and the respiratory clini-
cians were represented, to account for potential reporting
bias.
Both DAR and HES were reviewed for four binary
safety outcomes: procedural complications, post-
procedure overnight stay, readmissions and A&E atten-
dances within 30 days following the BT procedure. Using
an anonymised matching technique, records in both
sources were identified and referred to as the ‘matched
cohort’. This ‘matched cohort’ was used to count proce-
dures which had an event reported in either DAR, HES or
both, and hence to calculate combined safety outcomes.
As BT is usually delivered in three treatments, the first
(BT1), second (BT2) and third (BT3) procedures were
analysed separately to look for any differences between
them.
HES—procedural complications
In HES, a procedural complication was identified if the
episode contained certain combinations of International
Classification of Diseases (ICD-10) codes [27].
HES—readmissions within  days
These included any in-patient admission within 30 days
of the BT procedure, ensuring that admissions for subse-
quent BT procedures that happened to fall within 30 days
were excluded. The subset of potential emergency, respi-
ratory readmissions was also identified using HES fields
for admission method and diagnosis; the BT steering
group reviewed the ICD-10 diagnoses codes to verify the
reason for admission.
HES—A&E attendances within  days
These included any A&E attendance within 30 days of the
BT procedure. The subset of respiratory A&E attendances
which did not result in a hospital admission was also
identified. This ensured that an A&E attendance which
resulted in a hospital admission was not counted as two
events.
HES—post-procedure overnight stay
Episodes that involved an overnight stay were identified if
the date of discharge was after the date of procedure.
DAR—procedural complications
These included procedures with an entry in the ‘Unan-
ticipated Procedural Morbidity’ field reporting a
complication.
DAR—readmissions within  days
Several fields in DAR records were checked for the men-
tion of readmission within 30 days including the fields for
‘AnyHospital Admissions Since Last Treatment’, ‘Unantic-
ipated Procedural Morbidity’ and ‘Clinical Summary’ (of
the procedure and follow-up records).
DAR—A&E attendances within  days
As above, the same fields were checked for any mention
of A&E attendance within 30 days.
DAR—post-procedure overnight stay
These included procedure records where the ‘Duration of
Admission’ field was more than 24 hours.
Matching DAR andHES records
A combination of automatic and manual methods was
used to match procedure records between DAR and HES.
The criteria for matching between DAR and HES were:
the treatment centre (hospital) and sex were required to
match exactly, the HES procedure date and DAR proce-
dure date were required to be within 2 days (or the DAR
procedure date fell between the HES admission and dis-
charge dates) and the difference in age was required to be
no more than 1 year. Capture–recapture analysis [28] was
used to obtain the maximum likelihood estimate of the
true number of procedures undertaken and an estimated
coverage for each data source (DAR and HES).
Consideration of censored data
In DAR, readmissions and A&E attendances following
the final elective procedures (normally BT3) are usually
reported at the six-month follow-up visit. If the final
elective procedure was administered before 31 July 2014
(6months prior to end of study period) and no six-month
follow-up information was available, then the procedure
was treated as having no reported readmissions or A&E
attendances. If the final elective procedure was after 31
July 2014 and no follow-up record was available (e.g.
follow-up appointment scheduled after the study end-
date), the procedure was excluded from the analysis of
readmissions and A&E attendances. In DAR andHES, BT
procedures within 30 days of the study end-period were
excluded from analysis.
Statistics
Fisher’s exact test was used to test for differences between
the proportions of BT1, BT2 and BT3 procedures with a
reported respiratory event (in DAR) and with a reported
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Table . Baseline characteristics of BT patients.
All patients Matched patients
DAR HES DAR HES
Mean age at BT
(years)
.± . (n = )
Range –
.± . (n = )
Range –
.± . (n = )
Range –
.± . (n = )
Range –
Female (%) . . . .
complication, 30-day readmission or 30-day A&E atten-
dance (in DAR and HES). Confidence intervals of pro-
portions were calculated using the Clopper and Pearson
method; proportions were compared using χ2 test with
continuity correction. Analysis was performed using the
‘R’ statistical programming language [29] with a signifi-
cance level of 5%.
Results
DAR andHESmatching
In total, 215 BT procedures (83 patients) were extracted
from DAR and 203 BT procedure episodes (85 patients)
were extracted from HES. Of these, 152 procedures (59
patients) could be matched. 63 procedures in DAR were
not matched inHES. The known reasons for being unable
to match these included: 43 were from centres outside
of England; three were known to have used a different
method of reimbursement which meant that the proce-
dureswere not available fromHES. The remaining 17 pro-
cedures were likely to have been miscoded in HES and
therefore not identified by our search rules. From HES,
51 procedure episodes had nomatching DAR record. The
known reasons for not being able tomatch these included:
three procedures were conducted in one patient who did
not consent to data entry into DAR. Of the remaining 48
unmatched cases, some may have been miscoded in HES
and therefore not BT procedures while others may not
have had data entered in DAR at the time of data extrac-
tion. The sole manufacturer of the BT device confirmed
that there were noUK centres carrying out BT procedures
who were not contributing data to DAR.
Considering cases in England only (DAR 172, HES
203), the total number of procedures (including those
captured in neither database) was estimated to be 230,
using capture–recapture analysis [28] with maximum
likelihood estimation. Based on this, the estimated cov-
erage of DAR is 172/230 = 74.8% and the estimated cov-
erage of HES is 203/230 = 88.3%. Approximately two
thirds (152/230 = 66.1%) had records in both sources.
Patient characteristics
Table 1 shows the baseline characteristics of patients in
DAR, HES and the matched cohort. This shows the two
cohorts to have comparable demographic and disease
characteristics. Table 2 shows the baseline characteristics
of patients in DAR (total and matched cohort), compared
with those enrolled in three clinical trials (AIR (Asthma
Intervention Research) [1], AIR2 [2] and RISA (Research
in Severe Asthma) [3]); patients selected to receive BT
in routine clinical practice were, on average, older, had
lower baseline FEV1 (except for RISA trial) and lower
AQLQ scores. Baseline FEV1 and AQLQ data were avail-
able for 51/59 and 34/59 patients in the matched cohort
respectively.
Safety outcomes
Table 3 reports the safety outcomes from all DAR pro-
cedures, all HES procedure episodes and the matched
cohort. There were no significant differences in any of
the measures of safety (procedural complications, post-
procedure overnight stay, readmissions and A&E atten-
dances within 30 days) between BT1, BT2 and BT3 (the
Table . Baseline characteristics of BT patients compared with control (C) groups.
DAR
DAR (matched
cohort) AIR trial AIR trial RISA trial
Mean age (years) .± .
(na = )
Range –
.± . (n = )
Range –
.± .
(BT, n = )
.± .
(C, n = )
.± .
(BT, n = )
.± .
(C, n = )
.± .
(BT, n = )
.± .
(C, n = )
% female    (BT),  (C)  (BT),  (C)  (BT), (C)
Pre-bronch FEV
(% predicted)
.± .
(n = )
Range: –
.± . (n = )
Range –
.± . (BT)
.± . (C)
.± . (BT)
.± . (C)
.± . (BT)
.± . (C)
AQLQ score .± . (n = )
Range .–.
.± . (n = )
Range .–.
.± . (BT)
.± . (C)
.± . (BT)
.± . (C)
.± . (BT)
.± . (C)
a n is the number of patients for whom data were available.
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Table . Safety outcomes.
All procedures Matched procedures
DAR HES DAR HES Combineda
Procedures with any reported
respiratory event (%;%
CI)
/ (.;.-.) - / (.; .-.) - -
Procedures with complications
(%;% CI)
/ (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
Procedures followed by readmission within  days:
a) for any cause (%;% CI) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
b) for respiratory cause AND
emergency admission
(%;% CI)
/ (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
Procedures followed by A&E attendance within  days:
a) for any cause (%;% CI) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
b) for respiratory cause AND
not admitted (%;% CI)
/ (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
Procedures followed by
overnight stay (%;% CI)
/ (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.) / (.; .-.)
a Matched procedures with an event reported in either DAR or HES alone, or both.
online supplement contains all data for BT1, BT2 and
BT3 reported separately, together with analyses of the
differences).
In DAR, 41/215 BT procedures (19.1%) mentioned
a respiratory event, however only 16/215 (7.4%)
reported unanticipated events. In total, 73 events (in
27/83 patients) were reported and of these, 36 were
related specifically to asthma: wheeze (15), exacer-
bation/acute asthma attack (12), drop in FEV1 (5),
bronchospasm (3) and deterioration of asthma (1).
Some form of breathlessness/infection worsening was
seen in 28: chest pain/twinges/tightness (12), shortness
of breath/dyspnoea (4), cough/production of sputum
(6), chest infection/pneumonia (4) and raised tem-
perature/pyrexia (2). Rare reports included: inflamed
airways/bleeding (2), significant desaturation (1), slight
atelectasis (1), LLL (left lower lobe) collapse (1), left rib
fracture (1), metabolic acidosis/lactic acidosis (1) and
procedure being stopped/early termination (2). There
were only two recorded device problems, both related to
catheters; one was changed after two activations when a
spark was noticed, in another kinking and infolding was
reported after treatment of the right upper lobe.
For the four binary safety outcomes, only the data
from the matched cohort (152 procedures) were used
to calculate the event rates. One reason for this is that
they are all confirmed BT cases, whereas some cases
in HES may be miscoded and not BT procedures. In
addition, there are cases from the matched cohort which
report events in DAR that are not recorded in HES and
vice versa, so counting procedures which have an event
reported in either DAR, HES or both may be considered
to give a reliable estimate of the true rates. Contingency
Tables 4–6 illustrate the occurrences of safety events in
the matched cohort.
In the matched cohort, procedural complications were
reported in 17/152 procedures (11.2%; 13/59 patients),
but these did not correspond between DAR and HES in
all cases.
In general there were more reports of 30-day read-
missions in HES than in DAR (for any cause and any
admission method), however the 30-day readmissions
considered relevant to BT safety outcomes were emer-
gency readmissions for respiratory cause, rather than all-
cause/planned readmissions. Of the emergency readmis-
sions recorded in HES, four were excluded on the basis
of being non-respiratory cause after review by the BT
steering group (ICD-10 main codes R10.3, N39.0, A41.9
and T82.7). In the matched cohort, 18/152 procedures
(11.8%; 15/59 patients) were followed by an emergency
readmission within 30 days for respiratory cause. ICD-10
Table . Matched cohort: numbers of procedures with procedural
complications in DAR or HES alone, or both.
DAR—Y DAR—N Total
HES—Y   
HES—N   
Total   
Table . Matched cohort: numbers of procedures followed by
emergency respiratory readmission within  days in DAR or HES
alone, or both.
DAR—Y DAR—N Total
HES—Y  a 
HES—N   
Total   
a  DAR case had missing data.
Table . Matched cohort: numbers of procedures followed by res-
piratory A&E attendance within  days (without hospital admis-
sion) in DAR or HES alone, or both.
DAR—Y DAR—N Total
HES—Y   
HES—N   
Total   
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codes can also identify whether a readmission was due to
a complication of a previous procedure and only four of
the cases in HES were coded as such.
In thematched cohort, 13/152 procedures (8.6%; 13/59
patients) were followed within 30 days by an A&E admis-
sion for any cause. A&E attendances were rarely reported
in DAR however, and the reason for attendance was not
always reported in HES, leaving only 1/152 procedures
(0.7%) followed within 30 days by an A&E attendance
positively recorded as respiratory cause, and not resulting
in a hospital admission.
Overall, 31/152 procedures (20.4%) in the matched
cohort were associated with at least one safety issue (pro-
cedural complication, emergency respiratory readmission
or respiratory A&E attendance (without subsequent hos-
pital admission) within 30 days).
In the matched cohort, 70/152 procedures (46.1%)
were followed by an overnight stay. However, the pro-
portions of procedures followed by an overnight stay
were reported as significantly higher in HES (47.4%)
than in DAR (21.9%), p < 0.01. There was no significant
difference in the rates of overnight stay between BT1,
BT2 and BT3.
Discussion
This is the first presentation of ‘real-world’ clinical reg-
istry data for BT and there are no similar data anywhere
worldwide. The aim of this study is to publish procedural
and short-term safety outcomes of BT in routine clinical
practice and it focuses on the safety of the procedure
as assessed by registry data which have been validated
against routine hospital statistics. The strength of our
study is that we have achieved almost 100% UK cov-
erage of BT procedures being carried out post licence
through the use of the two independent data sources.
Additionally, we were able to obtain confirmation from
the sole manufacturer of the BT device that there were
no UK centres carrying out BT procedures who were not
contributing data to DAR. DAR was used to capture early
clinical experience of BT in the UK. HES was used to
assess coverage of DAR and to obtain independent safety
information for procedures carried out in England.
This study found that 20.4% of procedures in the
matched cohort were affected by at least one safety
issue [procedural complication, emergency respiratory
readmission or respiratory A&E attendance (without
subsequent hospital admission) within 30 days]. The
safety data reported here are not directly comparable
with the measures reported in previous trials, however
the reported hospitalisation rates for the previous trials
may be an indication of safety: AIR2 [1] 8.4% (16/190),
AIR [2] 7.3% (4/55) and RISA [3], 26.7% (4/15). The
explanation for the apparently higher rate of safety events
in clinical practice compared with AIR2 and AIR trials
could be related to the age and severity of the disease
of those treated, as the patients included in these two
clinical trials had moderate to severe asthma only. The
observed rate in clinical practice is closer to the RISA
study which included more severe asthma patients.
A benefit of using the matched cohort is that they are
all confirmed BT cases, and the information contained in
DAR and HES is combined to give a more reliable esti-
mate of safety event rates. However a limitation is that the
ratesmay be under- or over-estimates due to the reduction
in the denominator. For example the use of HES excludes
any group outside England, which in this studymeant that
43 procedures were excluded from the matched cohort.
A further benefit of using the matched cohort is to
help assess the extent of potential reporting bias. In DAR,
only events entered into the ‘Unanticipated Procedural
Morbidity’ field were reported as complications as these
may be considered potential safety issues. Centres were
encouraged to enter ‘unanticipated’ procedural morbid-
ity, so mild/expected events may be under-reported. On
the other hand, the reporting of such events (as free text)
is subjective, with some centres reporting more minor
events than others, and which may not be coded as com-
plications in HES. This could explain the higher number
of complications reported inDAR for thematched cohort.
In HES, variation in interpretation of clinical notes by
clinical coders could potentially lead to differences in
recording complications. For these reasons, any mention
of events inDARwhich could be regarded as being related
to safety were studied, with those related specifically to
asthma being reported.
Overall, many of the reported adverse events could
be perceived as ‘anticipated’ and only four cases of chest
infection/pneumonia and one case each of LLL collapse,
rib fracture andmetabolic acidosis were considered by the
BT steering group as significant ‘unanticipated events’.
A further strength of this study is that the two data
sources are independent and complementary. In general,
DAR contains richer clinical information about complica-
tions, reasons for overnight stay and hospital admissions,
though there is variation in how different centres com-
plete data fields. HES reported higher rates of readmission
andA&E attendance, possibly suggestingmore timely and
complete information. However, careful scrutiny of HES
fields for admission method and diagnoses was required
to ensure that planned readmissions, readmissions for
non-respiratory causes and A&E attendances for non-
respiratory causes were not included in the reported rate
of safety events following the BT procedure. Also, to avoid
double counting of events in HES, only A&E attendances
which did not subsequently result in a hospital admission
were included in the overall rate of safety events. A pos-
sible reason for the lower rates in DAR is that recording
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of healthcare usage may rely on patient recall of GP (gen-
eral practitioner) and hospital visits; additionally, patient
notes may be incomplete if an A&E attendance or read-
mission was to a different Trust than that which con-
ducted the BT procedure. Significant delays in record-
ing healthcare usage in DAR can also occur because this
information is only entered when the next procedure or 6
month follow-up has occurred.
There was an unexplained difference in the rate of
post-procedure stay reported by the two sources. Some
patients have planned pre-procedure admissions which
may potentially result in incorrect recording of procedure
dates in HES, and the 46.1% reported post-procedure stay
(combined data from the matched cohort) does appear
high compared with hospitalisation rates in previous tri-
als. The 21.9% rate for all procedures in DAR is closer to
the RISA trial and additionally, in DAR, some stays are
reported as precautionary which may be due to the sever-
ity of asthma in patients being treated in clinical practice.
Compared with three clinical trials, this study reported
that patients selected to receive BT in routine clinical
practice were on average older, had lower baseline FEV1
(except for RISA trial) and lower AQLQ scores. However,
baseline FEV1 and AQLQ data were not available for all
patients in thematched cohort, a consequence of registry-
based data collection rather than a clinical trial setting.
Conclusions
This paper presents, for the first time, an assessment of
procedural and short-term safety of BT in routine UK
clinical practice, using combined information from a clin-
ical registry with good coverage and routine administra-
tive data. The data suggest that a higher proportion of
patients are experiencing adverse events than reported by
two of the published clinical trials, however only a minor-
ity of these were considered significant by the treating
clinician. In addition, clinical practice has been to treat
patients with severity levels of asthma comparable with
the RISA trial population (high severity), rather than the
less severely affected patients in the pivotal AIR2 or AIR
studies (moderate to severe). The collection of registry
data has helped to place the findings of previous exper-
imental studies of BT in the context of routine clinical
practice and the ongoing data collection will enable a
study of longer term safety and clinical effectiveness when
data from a longer period of follow-up are available.
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